Abstracts tagged "Quality Indicators"

Abstract Number: 0409 • ACR Convergence 2025
Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Julia Harris¹, Leslie Favier², Emily Fox³, Jordan Jones², Michael Holland³, Cara Hoffart², Maria Ibarra³ and Ashley Cooper², ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, MO, ³Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Outcome assessment is essential to optimize care for patients with juvenile idiopathic arthritis (JIA). Although disease activity and patient-reported outcomes (PROs) are different measures,…
Abstract Number: 0228 • ACR Convergence 2025
Bridging the Gap: Leveraging eConsultation to Improve Access to Quality Gout Care
Laura Nichols¹ and Steven Taylor², ¹University of Colorado, Aurora, CO, ²University of Colorado, Denver, CO
Background/Purpose: In the context of the rheumatology workforce shortage, eConsultation holds significant potential to address some challenges through supporting primary care providers in managing rheumatologic…
Abstract Number: 0221 • ACR Convergence 2025
A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network
Grant Cannon¹, Beth Wallace², Deana Lazaro³, Pascale Schwab⁴, Paul Monach⁵, Ankoor Shah⁶, Gail Kerr⁷, Andreas Reimold⁸, Joshua Baker⁹, Gary Kunkel¹⁰, Katherine Wysham¹¹, Liron Caplan¹², John Richards¹³, Aleksander Lenert¹⁴, Andrew Jones¹⁵, Ted Mikuls¹⁶, Maria I. ("Maio") Danila¹⁷, Bryant England¹⁶, Brian Sauer¹⁸, Jorge Rojas¹⁹ and Isaac Smith²⁰, ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³VA New York Harbor Healthcare system, Short Hills, NJ, ⁴VA Portland and Oregon Health & Science University, Portland, OR, ⁵VA Boston Healthcare System, Boston, MA, ⁶Duke University, Durham, NC, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Dallas VA Medical Center, Dallas, TX, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ¹²Rocky Mountain Regional VAMC, Aurora, CO, ¹³Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁴University of Iowa, Iowa City, IA, ¹⁵VA Saint Louis and Washington University, Saint Louis, ¹⁶University of Nebraska Medical Center, Omaha, NE, ¹⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁸Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁹VA Puget Sound Health Care System, Seattle, WA, ²⁰Duke University Hospital, Durham, NC
Background/Purpose: Clinical guidelines recommend the use of disease activity measures (DAMs) in rheumatoid arthritis (RA) management. Measurement of DAMs is also a critical component of…
Abstract Number: 0218 • ACR Convergence 2025
Creating an EHR Lupus Outreach Workbench to Address Care Gaps
Ross Gilbert¹, Starla Blanks², Joy Buie³, Mary Cronin⁴, Jake Decker⁵, Laura Dickmann⁶, Cristina Drenkard⁷, Sancia Ferguson⁸, Shivani Garg⁹, David Gazeley⁵, Andrea Gilmore-Bykovskyi¹⁰, Gale Johnson¹¹, Patti Katz¹², Tristan Lazewski¹³, S. Sam Lim¹⁴, Jenna McGoldrick¹⁵, Katrina Phelps¹⁰, Edmond Ramly¹⁶, Rosalind Ramsey-Goldman¹⁷, Ann Rosenthal¹⁸, Dawn Thomas-Semanko¹⁹, Sarah Stoltz¹³, Patricia Tellez-giron²⁰, Amannda Weber²¹, Andrea Wipperfurth¹³ and Christie Bartels¹⁰, ¹Johns Hopkins University, Baltimore, MD, ²American College of Rheumatology, Atlanta, GA, ³Lupus Foundation of America, Washington, DC, ⁴retired, Fox Point, WI, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Froedtert Health, Waukesha, WI, ⁷Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA, ⁸University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, ⁹University of Madison, School of Medicine and Public Health, Madison, WI, ¹⁰University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹¹Wisconsin Department of Health Services, Madison, WI, ¹²UCSF, San Rafael, CA, ¹³UW Health, Madison, WI, ¹⁴Emory University School of Medicine, Atlanta, GA, ¹⁵SSM Health, Madison, WI, ¹⁶Indiana University - Bloomington, Bloomington, IN, ¹⁷Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁸Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Wisconsin, ¹⁹WI Chapter - LFA, Milwaukee, WI, ²⁰University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²¹University of Wisconsin (UW), UW Health, Madison, WI
Background/Purpose: Lupus affects up to 1.5 million people in the US with significant health disparities in care and outcomes that call for care delivery innovation.…
Abstract Number: 0191 • ACR Convergence 2025
Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK
Aoibhinn Kelly¹, Maddalena Rupnik², Nasra Ahmed¹, Mrinalini Dey³ and Elena Nikiphorou⁴, ¹King's College Hospital NHS Foundation Trust, London, United Kingdom, ²Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴King's College London, London, United Kingdom
Background/Purpose: Moderate disease in rheumatoid arthritis (RA) is defined as a 28-joint disease activity score (DAS28) of 3.2-5.1(MDAS). As per the National Institute for Health…
Abstract Number: 2440 • ACR Convergence 2025
Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study
Anca Askanase¹, Bruno Flamion², Ouali Berkani² and Cecile Dubois², ¹Columbia University Medical Center, New York, NY, ²Viatris Innovation, Allschwil, Switzerland
Background/Purpose: Cenerimod is a selective S1P1 receptor modulator that has the potential to reduce the abnormal immune response seen in Systemic lupus erythematosus (SLE) thereby…
Abstract Number: 1527 • ACR Convergence 2025
Lupus Nephritis Clinical Practice Guidelines: Critical Appraisal and Quality Comparison Using the AGREE II Tool
Egla Samantha Sanchez-Peralta¹, Hector Alejandro Martinez-Espinosa¹, Karla Paola Moncada-Flores², Margarita Isabel Alarcon-Jarquin³, Dionicio A. Galarza-Delgado⁴, Diana E. Flores-Alvarado¹ and Gabriel Figueroa-Parra⁵, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ²Internal Medicine, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: About a half of the patients with systemic lupus erythematosus (SLE) can present lupus nephritis (LN) throughout the course of their disease, representing one…
Abstract Number: 1283 • ACR Convergence 2025
Impact of Guideline Concordant Care of Renal Outcomes in Childhood-Onset Lupus Nephritis
Alisha Akinsete¹, Orysya Soroka², Mangala Rajan², Karen Onel³, Monika Safford² and Iris Navarro-Millan⁴, ¹Weill Cornell Medical Center, New York, NY, ²Weill Cornell Medicine, New York, ³HSS, New York, NY, ⁴Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY
Background/Purpose: End-stage renal disease (ESRD) is a serious complication of lupus nephritis (LN), yet the effect of guideline-concordant care on this outcome is unclear. Despite…
Abstract Number: 0199 • ACR Convergence 2024
Delivery of Guideline Concordant Care in Childhood-Onset Lupus Nephritis
Alisha Akinsete¹, Mangala Rajan², Orysya Soroka², Karen Onel³, Monika Safford² and Iris Navarro Millan⁴, ¹Weill Cornell Medicine/ Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³HSS, New York, NY, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: 50-80% of children with childhood-onset systemic lupus erythematosus (cSLE) develop lupus nephritis (LN). Children from historically marginalized communities are disproportionately affected by cSLE and…
Abstract Number: 0255 • ACR Convergence 2024
“Rheum” to Improve: Have Patients Attending the Young Adult Systemic Erythematosus (YASLE) Clinic Received All Appropriate Vaccinations? A Quality Improvement Initiative
Razan Al Yaarubi¹, Amanda Steiman¹ and Earl Silverman², ¹University of Toronto, Toronto, ON, Canada, ²Silverman, Toronto, ON, Canada
Background/Purpose: Infections are a leading cause of morbidity and mortality in patients with childhood-onset systemic lupus erythematosus (cSLE). Vaccination is a powerful tool to prevent…
Abstract Number: 0418 • ACR Convergence 2024
Improving Documentation of Contraception and Pregnancy Intention in Rheumatology Practice
Megan Clowse¹, Puneet Bajaj², Bonnie Bermas², Julie Chiesa³, Kathryn Dao⁴, Pamela Freeman⁵, Bansari Gujar⁶, Brittany Hill⁷, Kelley Jones⁸, Richard Jones⁹, Ann Marslett¹⁰, Brooke Mills¹¹, James Roberts², Amanda Snyderman⁸ and Leah Zulig¹², ¹Duke University, Chapel Hill, NC, ²UT Southwestern Medical Center, Dallas, TX, ³InfoDirectors, Durham, NC, ⁴Rheum101, Rockville, MD, ⁵Rheumatology Associates of Central Florida, Orlando, FL, ⁶Rheumatology Associates of Baltimore, Towson, MD, ⁷Clinic for Rheumatic Disease, Tuscaloosa, AL, ⁸Duke University School of Medicine, Durham, ⁹Clinic for Rheumatic Diseases, Northport, AL, ¹⁰Rheumatology Associates of Baltimore, Baltimore, MD, ¹¹UT Southwestern Medical Center, Fort Worth, TX, ¹²Duke University School of Medicine, Durham, NC
Background/Purpose: Prior studies of RISE Registry found 9-11% of women of reproductive age with contraception documentation. We sought to identify and assess methods to increase contraception documentation…
Abstract Number: 1067 • ACR Convergence 2024
Initiation of Urate-Lowering Therapy in Patients Hospitalized with Gout Flare at a Single Center: Opportunity for Quality Improvement
Ali Nasir¹ and Nasir Khan², ¹Trinity Health Grand Rapids/Michigan State University, Grand Rapids, MI, ²Trinity Health Grand Rapids, Grand Rapids, MI
Background/Purpose: Hospitalizations for gout flare have been increasing, doubling between 1993 to 2011 from 4.4 to 8.8 admissions per 100000 adults. Despite this increase, urate-lowering therapy (ULT)…
Abstract Number: 1069 • ACR Convergence 2024
Improving Triage Accuracy of Unclear Rheumatology Referrals: A Quality Improvement Study
Stephanie Gottheil¹, Chiara Gottheil² and Joseph Carson³, and Canadian Rheumatology Association - CIORA Grant, ¹London Rheumatology, London, ²London Rheumatology, London, Canada, ³London Rheumatology, London, ON, Canada
Background/Purpose: Patients with early inflammatory arthritis (EIA) need to be seen urgently to initiate treatment. Our community rheumatology clinic in Ontario, Canada was concerned that…
Abstract Number: 1078 • ACR Convergence 2024
Improving SLEDAI-2K Documentation for Childhood-Onset Systemic Lupus Erythematosus (cSLE) in a Pediatric Rheumatology Clinic Using Quality Improvement Methodology
Ivana Stojkic¹, Vinchelle Hardison¹, Fatima Barbar-Smiley², Mahmoud Kallash³, Hiren Patel³, Jonnie Lee Hughes³, James Gallop³, Ashlee Leone³, Emily Duff³, Alysha Taxter¹, Stacy Ardoin¹ and Vidya Sivaraman⁴, ¹Nationwide Children's Hospital, Columbus, OH, ²Amgen, Columbus, OH, ³Nationwide Children's Hosptial, Columbus, OH, ⁴Nationwide Children's Hospital/ The Ohio State University, Columbus, OH
Background/Purpose: Management of Systemic lupus erythematosus (SLE) requires accurate, timely disease activity monitoring for optimal treatment and research. The SLEDAI-2K provides objective clinical and laboratory…
Abstract Number: 1292 • ACR Convergence 2024
Primary Care Provider Educational Tool to Improve Osteoarthritis Management in the Primary Care Setting
Tessalyn Morrison¹, Luke Giangregorio², Emily Hadley-Strout¹ and Jeanne Gosselin³, ¹University of Vermont Medical Center, Burlington, VT, ²Larner College of Medicine at the University of Vermont, Burlington, VT, ³University of Vermont Medical Center, Waterbury, VT
Background/Purpose: Osteoarthritis is the most common form of arthritis and its prevalence is increasing. As a non-inflammatory type of arthritis, it can be managed in…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].